BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 23359498)

  • 1. Two rare disease-associated Tyk2 variants are catalytically impaired but signaling competent.
    Li Z; Gakovic M; Ragimbeau J; Eloranta ML; Rönnblom L; Michel F; Pellegrini S
    J Immunol; 2013 Mar; 190(5):2335-44. PubMed ID: 23359498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two common disease-associated TYK2 variants impact exon splicing and TYK2 dosage.
    Li Z; Rotival M; Patin E; Michel F; Pellegrini S
    PLoS One; 2020; 15(1):e0225289. PubMed ID: 31961910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Luteolin sensitizes the antiproliferative effect of interferon α/β by activation of Janus kinase/signal transducer and activator of transcription pathway signaling through protein kinase A-mediated inhibition of protein tyrosine phosphatase SHP-2 in cancer cells.
    Tai Z; Lin Y; He Y; Huang J; Guo J; Yang L; Zhang G; Wang F
    Cell Signal; 2014 Mar; 26(3):619-28. PubMed ID: 24333668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tyrosine kinase 2 is not limiting human antiviral type III interferon responses.
    Fuchs S; Kaiser-Labusch P; Bank J; Ammann S; Kolb-Kokocinski A; Edelbusch C; Omran H; Ehl S
    Eur J Immunol; 2016 Nov; 46(11):2639-2649. PubMed ID: 27615517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of TYK2 and JAK1 ameliorates imiquimod-induced psoriasis-like dermatitis by inhibiting IL-22 and the IL-23/IL-17 axis.
    Works MG; Yin F; Yin CC; Yiu Y; Shew K; Tran TT; Dunlap N; Lam J; Mitchell T; Reader J; Stein PL; D'Andrea A
    J Immunol; 2014 Oct; 193(7):3278-87. PubMed ID: 25156366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. JAK/STAT/SOCS-signaling pathway and colon and rectal cancer.
    Slattery ML; Lundgreen A; Kadlubar SA; Bondurant KL; Wolff RK
    Mol Carcinog; 2013 Feb; 52(2):155-66. PubMed ID: 22121102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural and Functional Characterization of the JH2 Pseudokinase Domain of JAK Family Tyrosine Kinase 2 (TYK2).
    Min X; Ungureanu D; Maxwell S; Hammarén H; Thibault S; Hillert EK; Ayres M; Greenfield B; Eksterowicz J; Gabel C; Walker N; Silvennoinen O; Wang Z
    J Biol Chem; 2015 Nov; 290(45):27261-27270. PubMed ID: 26359499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The
    Gorman JA; Hundhausen C; Kinsman M; Arkatkar T; Allenspach EJ; Clough C; West SE; Thomas K; Eken A; Khim S; Hale M; Oukka M; Jackson SW; Cerosaletti K; Buckner JH; Rawlings DJ
    Front Immunol; 2019; 10():44. PubMed ID: 30740104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression patterns of three JAK-STAT pathway genes in feather follicle development during chicken embryogenesis.
    Tao Y; Zhou X; Liu Z; Zhang X; Nie Y; Zheng X; Li S; Hu X; Yang G; Zhao Q; Mou C
    Gene Expr Patterns; 2020 Jan; 35():119078. PubMed ID: 31759166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. JAK kinases overexpression promotes in vitro cell transformation.
    Knoops L; Hornakova T; Royer Y; Constantinescu SN; Renauld JC
    Oncogene; 2008 Mar; 27(11):1511-9. PubMed ID: 17873904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Atlantic salmon protein tyrosine kinase Tyk2: molecular cloning, modulation of expression and function.
    Sobhkhez M; Hansen T; Iliev DB; Skjesol A; Jørgensen JB
    Dev Comp Immunol; 2013 Dec; 41(4):553-63. PubMed ID: 23872231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tuberculosis and impaired IL-23-dependent IFN-γ immunity in humans homozygous for a common
    Boisson-Dupuis S; Ramirez-Alejo N; Li Z; Patin E; Rao G; Kerner G; Lim CK; Krementsov DN; Hernandez N; Ma CS; Zhang Q; Markle J; Martinez-Barricarte R; Payne K; Fisch R; Deswarte C; Halpern J; Bouaziz M; Mulwa J; Sivanesan D; Lazarov T; Naves R; Garcia P; Itan Y; Boisson B; Checchi A; Jabot-Hanin F; Cobat A; Guennoun A; Jackson CC; Pekcan S; Caliskaner Z; Inostroza J; Costa-Carvalho BT; de Albuquerque JAT; Garcia-Ortiz H; Orozco L; Ozcelik T; Abid A; Rhorfi IA; Souhi H; Amrani HN; Zegmout A; Geissmann F; Michnick SW; Muller-Fleckenstein I; Fleckenstein B; Puel A; Ciancanelli MJ; Marr N; Abolhassani H; Balcells ME; Condino-Neto A; Strickler A; Abarca K; Teuscher C; Ochs HD; Reisli I; Sayar EH; El-Baghdadi J; Bustamante J; Hammarström L; Tangye SG; Pellegrini S; Quintana-Murci L; Abel L; Casanova JL
    Sci Immunol; 2018 Dec; 3(30):. PubMed ID: 30578352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Partial impairment of cytokine responses in Tyk2-deficient mice.
    Karaghiosoff M; Neubauer H; Lassnig C; Kovarik P; Schindler H; Pircher H; McCoy B; Bogdan C; Decker T; Brem G; Pfeffer K; Müller M
    Immunity; 2000 Oct; 13(4):549-60. PubMed ID: 11070173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of rare coding variants in
    Motegi T; Kochi Y; Matsuda K; Kubo M; Yamamoto K; Momozawa Y
    Ann Rheum Dis; 2019 Aug; 78(8):1062-1069. PubMed ID: 31118190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tyrosine Kinase 2-mediated Signal Transduction in T Lymphocytes Is Blocked by Pharmacological Stabilization of Its Pseudokinase Domain.
    Tokarski JS; Zupa-Fernandez A; Tredup JA; Pike K; Chang C; Xie D; Cheng L; Pedicord D; Muckelbauer J; Johnson SR; Wu S; Edavettal SC; Hong Y; Witmer MR; Elkin LL; Blat Y; Pitts WJ; Weinstein DS; Burke JR
    J Biol Chem; 2015 Apr; 290(17):11061-74. PubMed ID: 25762719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myxoma virus selectively disrupts type I interferon signaling in primary human fibroblasts by blocking the activation of the Janus kinase Tyk2.
    Wang F; Barrett JW; Shao Q; Gao X; Dekaban GA; McFadden G
    Virology; 2009 Apr; 387(1):136-46. PubMed ID: 19254804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure of the pseudokinase-kinase domains from protein kinase TYK2 reveals a mechanism for Janus kinase (JAK) autoinhibition.
    Lupardus PJ; Ultsch M; Wallweber H; Bir Kohli P; Johnson AR; Eigenbrot C
    Proc Natl Acad Sci U S A; 2014 Jun; 111(22):8025-30. PubMed ID: 24843152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IL-6 mediated activation of STAT3 bypasses Janus kinases in terminally differentiated B lineage cells.
    Kopantzev Y; Heller M; Swaminathan N; Rudikoff S
    Oncogene; 2002 Oct; 21(44):6791-800. PubMed ID: 12360405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allosteric TYK2 inhibition: redefining autoimmune disease therapy beyond JAK1-3 inhibitors.
    Jensen LT; Attfield KE; Feldmann M; Fugger L
    EBioMedicine; 2023 Nov; 97():104840. PubMed ID: 37863021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of IL-13- and IL-4-induced signaling in EBV-immortalized human B cells.
    Murata T; Puri RK
    Cell Immunol; 1997 Jan; 175(1):33-40. PubMed ID: 9015186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.